全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

维兰特罗关键中间体含量分析方法及其有关物质研究
Study on the Content Analysis Method of Key Intermediates of Vilanterol and Its Related Substances

DOI: 10.12677/HJMCe.2023.114026, PP. 213-223

Keywords: 维兰特罗,有关物质,方法学,含量测定,结构解析
Vilanterol
, Related Substances, Methodology, Content Determination, Structural Analysis

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:为建立一种新的HPLC法对维兰特罗中间体5及其有关物质分析检测的方法。方法:条件采用C18纳谱分析色谱柱(250 × 4.6 mm, 5 μm),流动相乙腈(A)-水(B),等度洗脱(80% A),流速1.0 mL?min?1,检测波长220 nm,经制备或半制备色谱分离有关物质,通过HPLC以及LC-MS分析,实现对中间体5及其有关物质进行定性和定量分析。结果:研究表明,中间体5在一定浓度范围内呈现出良好的线性关系(Y = 38705X + 21.565),平均加样回收率为100.61%~104.81%,RSD < 0.2%,重复性好(RSD < 0.5%),12 h内供试品溶液稳定(RSD < 2.0%)。利用此方法对中间体5及其有关物质含量进行测定,中间体5含量为98.0%~99.5%,主要杂质总含量为0.3%~0.6%,经定性结构分析判定杂质I (RT 1.47 min)为对甲苯磺酸,杂质III (RT 2.82 min)为中间体4,为合成中未除净的原料。结论:本研究为工艺优化、有效降低或去除杂质及关键中间体的质量控制提供理论和方法支撑。
Objective: In order to establish a new HPLC method for the determination of intermediate 5 of vilanterol and its related substances. Methods: The chromatographic analysis was performed on C18 nanoscopic column (250 × 4.6 mm, 5 μm) with mobile phase acetonitrile (A)-water (B) and isode-gree elution (80% A), and the flow rate was 1.0 min?mL?1. The detection wavelength was 220 nm, and the related substances were separated by preparative or semi-preparative chromatography. The qualitative and quantitative analysis of intermediate 5 and its related substances was realized by HPLC and LC-MS analysis. Results: The results showed that the intermediate 5 showed a good linear relationship in a certain concentration range (Y = 38705X + 21.565), the average recovery was 100.61%~104.81%, RSD < 0.2%, and the repeatability was good (RSD < 0.5%). The solution was stable within 12 h (RSD < 2.0%). The content of intermediate 5 and its related substances was determined by this method. The content of intermediate 5 was 98.0%~99.5%, and the total content of major impurities was 0.3%~0.6%. The impurity I (RT 1.47 min) was determined to be p-toluenesulfonic acid by qualitative structural analysis, and the impurity III (RT 2.82 min) was determined to be intermediate 4. It is the raw material not cleaned in synthesis. Conclusion: This study provides theoretical and methodological support for process optimization, effective reduction or removal of impurities and quality control of key intermediates.

References

[1]  Blair, H.A. and Deeks, E.D. (2015) Umeclidinium/Vilanterol: A Review of Its Use as Maintenance Therapy in Adults with Chronic Obstructive Pulmonary Disease. Drugs, 75, 61-74.
https://doi.org/10.1007/s40265-014-0326-1
[2]  Rosrigo, G.J. and Plzaz, V. (2016) Once-Daily Fluticasone Fu-roate and Vilanterol for Adolescents and Adults with Symptomatic Asthma a Systematic Review with Meta-Analysis. Annals of Allergy, Asthma & Immunology, 16, 565-570.
https://doi.org/10.1016/j.anai.2016.03.035
[3]  Slack, R.J., Barrett, V.J., Morrison, V.S., et al. (2013) In Vitro Pharmacological Characterization of Vilanterol, a Novel Long-Acting β2-Adrenoceptor Agonist with 24-Hour Duration of Action. Journal of Pharmacology and Experimental Therapeutics, 344, 218-230.
https://doi.org/10.1124/jpet.112.198481
[4]  Glaxo, G.L., Box, P.C., Coe, D.M., et al. (2003) Phenethanolamine Derivatives for Treatment of Respiratory Diseases. WO, 2002GB04140. 2003-03-27.
[5]  Procopiou, P.A., Barrett, V.J., Bevan, N.J., et al. (2010) Synthesis and Structure-Activity Relationships of Long-Acting β2 Adrenergic Receptor Agonists Incorporating Metabolic Inactivation: An Antedrug Approach. Journal of Medicinal Chemistry, 53, 4522-4530.
https://doi.org/10.1021/jm100326d
[6]  Perrigo Api Ltd. (2015) An Improved Process for the Preparation of Vi-lanterol and Intermediates Thereof. WO, EP3189053B1. 2015-08-27.
[7]  上海医药工业研究所, 中国医药研究医药工业研究总院. 一种维兰特罗中间体及其制备方法和应用[P]. 中国专利, 201410720451.2. 2016-06-08.
[8]  诸葛文云. 维兰特罗的合成工艺及关键中间体结晶研究[D]: [硕士学位论文]. 济南: 济南大学, 2019.
[9]  张启龙, 诸葛文云, 高令峰, 等. 维兰特罗关键手性中间体的合成工艺优化[J]. 中国医药工业杂志, 2020, 51(10): 1262-1265.
[10]  陈思毅. 维兰特罗手性中间体的合成及工艺改进[D]: [硕士学位论文]. 武汉: 武汉工程大学, 2018.
[11]  安徽德信佳生物医药有限公司. 一种在混合溶剂中合成维兰特罗中间体的方法[P]. 中国专利, 201910056494. 2019-04-05.
[12]  安徽德信佳生物医药有限公司. 一种固体酸催化合成维兰特罗中间体的方法[P]. 中国专利, 201910056310. 2019-04-05.
[13]  王敬赫, 邓少欢, 高俊, 等. 维兰特罗关键中间体的有关物质分析方法筛选及优化[J]. 药物化学, 2021, 9(4): 125-136.
[14]  晏海军, 陈一波, 张福利, 等. HPLC测定盐酸氯胺酮原料药中的有关物质[J]. 中国现代应用药学, 2022, 39(5): 633-637.
[15]  邵天舒, 郭雷, 李潇. HPLC法测定复方氨基酸注射液(18AA)中胱氨酸与半胱氨酸的含量及其在药品质量评价中的应用[J]. 中国医药工业杂志, 2022, 53(10): 1494-1498.
[16]  梁键谋, 朱坤丹, 罗英, 等. LC-MS测定双氢青蒿素哌喹片中阿莫西林、头孢克洛和头孢克肟的残留量[J]. 中国现代应用药学, 2022, 39(16): 2125-2129.
[17]  丁亚婷, 邱宏春, 尹山, 等. 布地奈德缓释片有关物质方法的建立及色谱-质谱结构鉴定[J]. 药物分析杂志, 2021, 41(10): 1796-1805.
[18]  肖亭, 王晨, 姚尚辰, 等. HPLC校正因子法在药物分析中的应用[J]. 药学学报, 2020, 55(12): 2854-2861.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413